Premature Labor (Tocolysis) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Premature Labor (Tocolysis) - Pipeline Review, H2 2016

Premature Labor (Tocolysis) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Premature Labor (Tocolysis) - Pipeline Review, H2 2016
Published Aug 24, 2016
60 pages — Published Aug 24, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Premature Labor (Tocolysis) - Pipeline Review, H2 2016, provides an overview of the Premature Labor (Tocolysis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
- The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects
- The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise correct

  
Source:
Document ID
GMDHC8400IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Premature Labor (Tocolysis) Overview71
Therapeutics Development82
  Pipeline Products for Premature Labor (Tocolysis) Overview81
  Pipeline Products for Premature Labor (Tocolysis) Comparative Analysis91
Premature Labor (Tocolysis) Therapeutics under Development by Companies101
Premature Labor (Tocolysis) Therapeutics under Investigation by Universities/Institutes111
Premature Labor (Tocolysis) Pipeline Products Glance124
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
  Unknown Stage Products151
Premature Labor (Tocolysis) Products under Development by Companies161
Premature Labor (Tocolysis) Products under Investigation by Universities/Institutes171
Premature Labor (Tocolysis) Companies Involved in Therapeutics Development186
  AMAG Pharmaceuticals, Inc.181
  GlaxoSmithKline Plc191
  Juniper Pharmaceuticals, Inc.201
  Kissei Pharmaceutical Co., Ltd.211
  Lipocine Inc.221
  ObsEva SA231
Premature Labor (Tocolysis) Therapeutics Assessment248
  Assessment by Monotherapy Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type311
Drug Profiles3214
  bedoradrine sulfate Drug Profile323
  hydroxyprogesterone caproate Drug Profile351
  hydroxyprogesterone caproate Drug Profile362
  OBE-001 Drug Profile382
  OBE-022 Drug Profile401
  progesterone Drug Profile411
  retosiban Drug Profile421
  Small Molecule for Acute Inflammation and Premature Labor Drug Profile431
  Small Molecule to Agonize Progesterone Receptor for Preterm Birth Drug Profile441
  Small Molecules for Premature Labor Drug Profile451
Premature Labor (Tocolysis) Dormant Projects461
Premature Labor (Tocolysis) Discontinued Products471
Premature Labor (Tocolysis) Product Development Milestones4811
  Featured News &Press Releases481
    Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor481
    Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)481
    Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)491
    Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women501
    Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301501
    Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena511
    Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection)511
    Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor521
    Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways521
    Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women531
    May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena541
    May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth541
    Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour551
    Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour561
    Jul 02, 2012: FDA Issues Further Guidance On K-V Pharma's Makena563
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Premature Labor (Tocolysis) - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Premature-Labor-Tocolysis-Pipeline-Review-H2-2016-2088-16441>
  
APA:
Global Markets Direct - Market Research. (2016). Premature Labor (Tocolysis) - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Premature-Labor-Tocolysis-Pipeline-Review-H2-2016-2088-16441>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.